Central and Peripheral Glucagon Reduces Hyperlipidemia in Rats and Hamsters

Abstract

Background

Increased lipid levels in blood contribute to increasing the risk of diabetic complications. Glucagon exerts lipid lowering effects in diabetic state. However, the mechanism behind the lipid reduction by glucagon independent of glucose homeostasis is not well understood. We assessed the actions of glucagon on lipid modulation in blood and markers in liver in hyperlipidemic hamsters and rats.

Methods

Male Sprague Dawley rats and Golden Syrian hamsters on a hyperlipidemic diet for 2 weeks were administered a single dose of glucagon by subcutaneous (SC, 150 and 300 µg/kg) or intracerebroventricular (ICV, 15 and 30 µg/animal) route. Effect of acute treatment was observed on tyloxapol-induced hypertriglyceridemia, corn oil-induced post-prandial lipemia, and bile flow. A repeated dose treatment by subcutaneous (300 µg/kg) or intracerebroventricular (30 µg/animal) route was done for 2 weeks, following which circulating and hepatic lipids, hepatic markers of lipid metabolism and bile flow were assessed.

Results

Acute administration of glucagon (SC and ICV) decreased triglyceride absorption, hepatic triglyceride secretion rate and increased excretion of cholesterol in bile fluid in dose related manner. Repeated dose treatment reduced circulating and hepatic lipids and mainly LDL, and enhanced cholesterol excretion in bile. In liver, expression of HMG-CoA reductase was reduced while that of ABCA1 was increased after repeated treatment, whereas pair fed group did not show significant changes when compared to the control group.

Conclusion

These findings demonstrate that central as well as peripheral glucagon effectively reduces hyperlipidemia in rat and hamster model, by modulating hepatic lipid metabolism.

Key words

bile homeostasis - ABCA1 - cholesterol - triglyceride

• References

• 1 Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119: 812-819
• 2 Han TS, Lean ME. A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSM Cardiovasc Dis 2016; 5: 2048004016633371
• 3 Malik S, Wong ND, Franklin SS. et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-1250
• 4 Gallwitz B. Glucagon-like peptide-1 analogues for type 2 diabetes mellitus: current and emerging agents. Drugs 2011; 71: 1675-1688
• 5 Pi-Sunyer X, Astrup A, Fujioka K. et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373: 11-22
• 6 Day JW, Ottaway N, Patterson JT. et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 2009; 5: 749-757
• 7 Pocai A, Carrington PE, Adams JR. et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 2009; 58: 2258-2266
• 8 Patel V, Joharapurkar A, Dhanesha N. et al. Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice. Can J Physiol Pharmacol 2013; 91: 1009-1015
• 9 Longuet C, Sinclair EM, Maida A. et al. The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab 2008; 8: 359-371
• 10 Ahren B. Glucagon–Early breakthroughs and recent discoveries. Peptides 2015; 67: 74-81
• 11 Parmley WW, Glick G, Sonnenblick EH. Cardiovascular effects of glucagon in man. N Engl J Med 1968; 279: 12-17
• 12 Mu J, Qureshi SA, Brady EJ. et al. Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist. PLoS One 2012; 7: e49572
• 13 Mighiu PI, Yue JT, Filippi BM. et al. Hypothalamic glucagon signaling inhibits hepatic glucose production. Nat Med 2013; 19: 766-772
• 14 Agarwala GC, Mishra R, Jaiswal G. et al. Effect of centrally administered glucagon on blood lipids in anesthetised dogs. Indian J Physiol Pharmacol 1986; 30: 280-288
• 15 Angelin B. 1994 Mack-Forster Award Lecture. Review. Studies on the regulation of hepatic cholesterol metabolism in humans. Eur J Clin Invest 1995; 25: 215-224
• 16 Patel V, Joharapurkar A, Dhanesha N. et al. Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice. Pharmacol Rep 2013; 65: 927-936
• 17 Quinones M, Al-Massadi O, Gallego R. et al. Hypothalamic CaMKKbeta mediates glucagon anorectic effect and its diet-induced resistance. Mol Metab 2015; 4: 961-970
• 18 Thiele TE, Seeley RJ, D'Alessio D. et al. Central infusion of glucagon-like peptide-1-(7-36) amide (GLP-1) receptor antagonist attenuates lithium chloride-induced c-Fos induction in rat brainstem. Brain Res 1998; 801: 164-170
• 19 Habegger KM, Stemmer K, Cheng C. et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 2013; 62: 1453-1463
• 20 Xiao C, Pavlic M, Szeto L. et al. Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans. Diabetes 2011; 60: 383-390
• 21 Schade DS, Woodside W, Eaton RP. The role of glucagon in the regulation of plasma lipids. Metabolism 1979; 28: 874-886
• 22 Guettet C, Mathe D, Riottot M. et al. Effects of chronic glucagon administration on cholesterol and bile acid metabolism. Biochim Biophys Acta 1988; 963: 215-223
• 23 Jablonska A. Effect of glucagon on serum cholesterol and urinary excretion of 17-hydroxycorticosteroids. Pol Tyg Lek 1973; 28: 203-205
• 24 Tsutsumi K, Hagi A, Inoue Y. The relationship between plasma high density lipoprotein cholesterol levels and cholesteryl ester transfer protein activity in six species of healthy experimental animals. Biological and pharmaceutical bulletin 2001; 24: 579-581
• 25 Russell JC, Proctor SD. Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovascular Pathology 2006; 15: 318-330
• 26 Casaschi A, Maiyoh GK, Adeli K. et al. Increased diacylglycerol acyltransferase activity is associated with triglyceride accumulation in tissues of diet-induced insulin-resistant hyperlipidemic hamsters. Metabolism 2005; 54: 403-409
• 27 Mawatari K, Kakui S, Harada N. et al. Endothelin-1 (1–31) levels are increased in atherosclerotic lesions of the thoracic aorta of hypercholesterolemic hamsters. Atherosclerosis 2004; 175: 203-212
• 28 Auger C, Rouanet JM, Vanderlinde R. et al. Polyphenols-enriched Chardonnay white wine and sparkling Pinot Noir red wine identically prevent early atherosclerosis in hamsters. Journal of Agricultural and Food Chemistry 2005; 53: 9823-9829
• 29 Wang S, Smith JD. ABCA1 and nascent HDL biogenesis. Biofactors 2014; 40: 547-554
• 30 Vaisman BL, Lambert G, Amar M. et al. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest 2001; 108: 303-309
• 31 Lakshmanan MR, Nepokroeff CM, Ness GC. et al. Stimulation by insulin of rat liver -hydroxy- -methylglutaryl coenzyme A reductase and cholesterol-synthesizing activities. Biochem Biophys Res Commun 1973; 50: 704-710
• 32 Hsieh J, Longuet C, Baker CL. et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010; 53: 552-561
• 33 Patel V, Joharapurkar AA, Kshirsagar SG. et al. Central GLP-1 receptor activation improves cholesterol metabolism partially independent of its effect on food intake. Can J Physiol Pharmacol 2015; 29: 1-7